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The Dialysis Outcomes Quality Initiative emphasizes
increasing arteriovenous fistula prevalence, by promoting
referral for fistula creation in patients with stage 4 chronic
kidney disease (CKD). The aim is to provide an optimal access
for initiation of dialysis, thus avoiding central venous catheter
use. The endovascular management of nonmaturing fistulas
is more complicated in these patients, where the expected
benefit of catheter avoidance must be weighed against the
risk of contrast induced nephropathy (CIN). This study reports
on the safety of a low-dose radiocontrast regimen, used in
performing endovascular fistula salvage procedures in
patients with stage 4 CKD. All consecutive endovascular
procedures performed over a 2-year period in patients with
stage 4 CKD and nonmaturing access were identified. Data
collected included the type of procedure, contrast volume
per procedure, pre, 2- and 7-day creatinine, need for acute
dialysis, and the type of access used to initiate dialysis. Total
of 65 procedures were performed in 34 patients. The mean
contrast volume was 7.8 ml per procedure. The incidence of
CIN (25% increase in serum creatinine) was 4% at 2 days and
4.6% at 1 week. All values returned to baseline within 2
weeks, and no patient required acute dialysis. Among the 33
patients with nonmaturing fistulas, 20 initiated dialysis
during the follow-up period, 15 (75%) using their fistula, and
five (25%) using a catheter. This study demonstrates that in
patients with advanced CKD, fistulas can be successfully
salvaged using small contrast volumes with a low incidence
of CIN.
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Contrast-induced nephropathy (CIN) is a well-recognized
cause of acute renal failure. Chronic kidney disease (CKD)
with impaired glomerular filtration rate is the most
important risk factor for CIN,1–3 and diabetes with impaired
glomerular filtration rate confers a higher CIN risk than renal
dysfunction alone. Measures taken to reduce CIN in high-risk
patients include minimizing the radiocontrast dose,4–6
selection of a low osmolar contrast media,2 intravenous
bicarbonate infusion,7 and avoidance of volume depletion
using intravenous half-normal or normal saline.8–11 Unfortu-
nately, the available literature does not define a safe contrast
dose. General consensus is the use of the smallest dose of
contrast to achieve an acceptable outcome. For many
cardiovascular and radiological procedures, these doses range
from 50 to 300 ml, and typically more than 100 ml of contrast
is employed. Dialysis access endovascular procedures require
considerably lower doses with a range from 10 to 50 ml.
Recent studies have shown that autologous arteriovenous
fistulas (AVF) have a significant initial failure rate ranging
between 20 and 50%.12 However, the practice of abandoning
nonmaturing fistulas is challenged by studies in which the
majority of immature AVF were salvaged to support dialysis,
using a variety of interventions.13,14 Until recently, the
majority of procedures for nonmaturing access were
performed in patients already established on hemodialysis
(HD). Here, the risk of radiocontrast use is limited to the
uncommon adverse allergic reactions and occasional volume
overload when large contrast volumes are used. The Dialysis
Outcomes Quality Initiative15 and the ‘Fistula First’ National
Vascular Access Improvement Initiative16 emphasize increas-
ing AVF prevalence, in part by promoting early referral for
AVF creation. These initiatives will undoubtedly result in an
increase in the number of patients with stage 4 CKD and
fistulas. The aim of early fistula creation is to provide an
optimal access for the initiation of HD, thus entirely avoiding
central venous catheter use. The management of nonmatur-
ing or thrombosed fistulas is more complicated in patients
with CKD, where the expected benefit of catheter avoidance
must be weighed against the CIN risk in a setting of reduced
glomerular filtration rate. This paper describes the experience
of an interventional nephrology center in performing fistula
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salvage procedures in patients with stage 4 CKD, using a low-
dose radiocontrast regimen, with particular focus on the
incidence of CIN.
RESULTS
Baseline demographic and clinical characteristics are sum-
marized in Table 1. The mean age was 68 years, and 38% of
the patients were over the age of 75. In total, 20 patients
(59%) were diabetic. A total of 65 procedures were
performed. The volume of contrast ranged from 1.5 to
25 ml per procedure (mean 7.875.2 ml; median 6 ml).
Therefore, the total volume of diluted contrast (combined
in a 1:3 ratio with saline) was four times these values (mean
31.2 ml). The preprocedure mean creatinine was 4.37 mg/dl.
For all patients, an estimation of the baseline glomerular
filtration rate was performed using the Modification of Diet
in Renal Disease formula. This showed a mean glomerular
filtration rate of 16 (median 14; range 6–33).
Renal outcomes
Preprocedure and 7-day creatinine levels were available for all
65 procedures (Table 2). The 2-day creatinine was available
for 50 procedures. There was a small and nonsignificant
increase in mean serum creatinine at day 2 (þ 0.04 mg/dl;
95% CI: 0.14, þ 0.23) and day 7 (þ 0.11 mg/dl; 95% CI:
0.02, þ 0.23; P¼ 0.09 for the comparison between
preprocedure and 7-day creatinine). CIN, defined as a 25%
increase in serum creatinine, occurred following two
procedures (4%) at day 2, and three procedures (4.6%) at
day 7. In all cases, creatinine values returned to baseline
within 2 weeks, and there were no episodes of CIN requiring
dialysis. There was no relationship between the volume of
contrast and the occurrence of CIN in this cohort, with four
of five CIN episodes occurring after the infusion of contrast
volumes below the median dose of 6 ml. The percentage
change in serum creatinine was similar whether the
procedure was performed using contrast volumes p or 4
than the median dose of 6 ml (P¼ 0.7).
Table 3 summarizes characteristics and outcomes of
procedures by diabetic status. The mean preprocedure
creatinine was 4.4 mg/dl, with a nonsignificant trend towards
higher preprocedure creatinine in non-diabetics (4.7 versus
4.0 mg/dl; P¼ 0.1). The mean volume of contrast did not
differ significantly between diabetics and non-diabetics (8.1
versus 7.2 ml; P¼ 0.5). The mean percentage change in serum
creatinine at day 7 was þ 3%, and did not vary significantly
by diabetic status (P¼ 0.6).
Procedures characteristics and outcomes
A total of 65 procedures were performed in 34 patients
(average 1.9 procedures/patient). A total of 62 procedures
were performed in 33 patients with fistulas, and three
procedures were performed in a single patient with a graft.
There were 57 episodes of venography and angioplasty in 29
patients with nonmaturing access, and eight thrombectomies
in five patients with clotted access (mean volume of contrast
used for thrombectomies was 7.9 ml). Two patients experi-
enced mild extravasations and grade I hematomas. There
were no major complications.
For nonmaturing fistulas, location and the lesions treated
are summarized in Table 4. A total of 85 lesions were treated
(1.5 lesions per procedure). Arterial anastamosis and Juxta-
anastamotic segment lesions were more common in the
forearm access, and fistula body and cephalic arch lesions
were more prevalent in the upper arm fistula. Four patients
with fistulas underwent six thrombectomies. Immediate
anatomic success was achieved in five of these procedures.
One patient started dialysis using the fistula, and one patient
remained dialysis-independent with a patent fistula at the
Table 1 | Demographic characteristics
Age (mean7s.d) 68713 years
Male 20 (59%)
Diabetes 20 (59%)
Race
Caucasian 23 (68%)
Hispanic 7 (20%)
African American 3 (9%)
Asian 1 (3%)
Table 2 | Renal outcomes (all procedures)
Preprocedure (n=65) Day 2 (n=50) Day 7 (n=65)
Creatinine (mg/dl) 4.37 (4.0–4.8) 4.64 (4.1–5.2) 4.47 (4.1–4.9)
Change in creatinine (mg/dl) +0.04 (0.1 to +0.2) +0.1 (0.02 to +0.2)
% Change in creatinine (%) +1.3 (2.6 to +5.1) +3.0 (+2.5 to +5.7)
425% rise in creatinine 2/50 (4%) 3/65 (4.6%)
Data are reported as means (95% confidence intervals) for continuous variables and as proportions for categorical variables. The P-value for the difference between the mean
preprocedure and 7-day creatinine values is 0.09 (paired t-test).
Table 3 | Renal outcomes by diabetic status
Diabetes (n=39)
No diabetes
(n=26) P-value
Preprocedure
creatinine (mg/dl)
4.0 (3.6–4.5) 4.7 (4.0–5.3) 0.1
Contrast volume (ml) 8.1 (6.2–10.1) 7.2 (5.7–8.7) 0.5
Change in creatinine
at day 7 (mg/dl)
+0.12 (0.16, +0.28) +0.09 (0.12, +0.28) 0.9
% Change in
creatinine at day 7
+ 3.7 (0.0, +7.3) +2.1 (2.3, +6.5) 0.6
Data are reported as means (95% confidence intervals) for continuous variables.
Reported P-values are for the comparison between diabetic and non-diabetic
patients.
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end of the study period. In two patients, the access was
eventually abandoned. The single patient with the graft
required two thrombectomies. During the follow-up period,
the patient had not yet initiated dialysis and the graft
remained patent.
By the end of the study period, 15 of the 33 patients with
fistulas had started dialysis using the fistula (46%), 13 (39%)
remained in stage 4 CKD, and 5 (15%) patients required a
catheter at the initiation of dialysis.
DISSCUSSION
While programs aimed at improving vascular access manage-
ment in prevalent HD patients are important, the success of
any vascular access quality improvement initiative requires
reduction of the number of incident HD patients treated with
a catheter.17,18 Guideline 8 of Dialysis Outcomes Quality
Initiative proposes proactive access planning during stage 4
CKD.15 The ‘Fistula First’ initiative includes 11 concepts to
foster AVF prevalence, one of which is the ‘fistula only’
vascular surgery consult for stage 4 CKD patients.16 Multiple
steps are involved in increasing the number of patients that
start HD with a functional AVF.12–13,19 An important part of
the vascular access cycle from creation to cannulation is the
postoperative monitoring and correction of lesions in
immature and failing fistulas. Barriers to provision of these
services result in an increase in emergency access procedures
and emergent use of catheters for dialysis.20
Concern regarding the consequences of CIN may cause
nephrologists to delay fistulography until the CKD patient
with an immature fistula is established on dialysis via a
central venous catheter. Some fistulas may require more than
a single procedure and added time to mature, and some
fistulas may never mature despite the interventions. This may
unnecessarily prolong catheter use with an associated risk of
inadequate dialysis dose delivery, infection, and central
venous stenosis. There is a window of opportunity to treat
these fistulas before HD initiation.
Several inconclusive studies were designed to define a safe
contrast dose for interventional procedures. Cigarroa et al.4
published the first such study in 1989 on patients with CKD
undergoing cardiac catheterization. The authors devised an
empiric formula to calculate a safe radiocontrast dose based
on the patient’s weight and level of renal function, where the
maximal radiocontrast dose is equal to 5 body weight
(kg)/serum creatinine (mg/dl). There was a statistically
significant lower incidence of CIN in patients with a contrast
dose below the maximal radiocontrast dose. Despite the
obvious limitations of this study, this was the first attempt to
create a guideline for contrast use using an empiric formula.
Other interventional cardiologists have attempted to validate
the maximal radiocontrast dose formula.6 However, the wide
variations in the contrast volume administered (100–300 ml)
and different contrast agents employed in these studies make
comparisons difficult.
In 1990, Manske et al.5 assessed contrast nephropathy in
patients with diabetes and advanced renal dysfunction.
Patients were undergoing diagnostic cardiac catheterization;
therefore, smaller doses of contrast were used (mean 31 ml).
This group reported that volumes of nonionic contrast
material (iohexol or iopamidol) greater than 30 ml were
associated with markedly increased incidence of CIN in this
high-risk population. Even patients receiving doses as low as
20 ml were susceptible to developing CIN. In a more recent
prospective study, however, low-dose radiocontrast adminis-
tration was shown to be safe in a group of high-risk patients.
Asif et al. assessed the incidence of CIN in advanced CKD
patients with a 50% rate of diabetes, undergoing venography
for venous mapping. A total of 21 patients with stage 4 or 5
CKD showed no evidence of CIN after receiving 10–20 ml of a
low-osmolar contrast agent.21
Percutaneous AV fistulography requires a significantly
lower contrast volume than cardiac and other radiology
procedures. Our study suggests that low doses (mean 7.8 ml,
range 1.5–25 ml) of a nonionic, low-osmolar contrast agent
can be used safely even in patients at a high risk for CIN. In
this cohort of patients with stage 4 CKD and a high
prevalence of diabetes, the incidence of CIN was 4% at 2 days
and 4.6% at 1 week. All values returned to baseline within 2
weeks, and no patient required acute dialysis. Although the
study population had a high proportion of diabetics, there
was no increased CIN incidence in this group. From the total
of 65 procedures, 31 were repeat procedures due to various
reasons, including persistent immaturity, thrombosis, re-
study of resistant lesions, and planned two-step procedures.
Although CIN occurred more frequently after repeat
procedures (3/31 or 10%), the long interval between
procedures (median 64 days, range 7–334 days) makes it
difficult to determine whether the increased risk is attribu-
table to repeated contrast exposure or to progression of
underlying CKD. None of the 7 repeat procedures performed
within 30 days were complicated by CIN; however, our ability
to draw conclusions about the risk of repeat procedures is
limited by the small subgroup sample size and the low
incidence of CIN with the use of a low-contrast protocol.
Physical assessment is essential prior to intervention on an
immature fistula.22 This allows the interventionalist to
clinically locate the most significant lesion, thus tailoring
the procedure to treat the most important lesions. In this
study, an average of 1.9 procedures per patient were required.
Some of these were part of a staged procedure, thus avoiding
excessive contrast use in a single procedure. For forearm
Table 4 | Site of lesions in relation to access location
Site of lesion
Forearm fistula
(22 procedures)
Upper arm fistula
(35 procedures)
Arterial, arterial anastamosis 7 2
JAS 9 9
AVF body 8 15
Cephalic arch 0 17
Central 0 1
Accessory vein ligation 7 8
AVF, arteriovenous fistulas; JAS, Juxta-anastamotic segment.
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fistula, the majority of the treated lesions were at the inflow,
and for the upper arm fistula at the main venous body and
the outflow draining veins. By the end of the study period, 20
of the 33 patients with fistulas had started dialysis, 15 (75%)
using their fistula and only 5 (25%) patients required a
catheter at the initiation of dialysis. Four fistulas required six
thrombectomy procedures. Two of these fistulas were patent
at the end of the study period, with one being used for HD.
While many centers do not perform fistula thrombectomies
even in end-stage renal disease patients, this study suggests
that the procedure can be safely performed in CKD patients.
Although interventional nephrology is a growing field,
highly experienced interventionalists who dedicate a sub-
stantial proportion of their professional activities to dialysis
access procedures are not universally available to CKD
programs. The findings of this study may not be applicable to
regions with limited availability of experienced and dedicated
interventionalists. The isotonic saline infused preprocedure
in each patient may have played a role in the apparent safety
of contrast use. Distinguishing the relative CIN prophylactic
contribution of saline infusion and using low contrast dose
by a 1:3 saline dilution is not possible. It is important to note
that diluting the contrast in a 1:3 ratio with saline (1 ml of
contrast and 3 ml of normal saline, predrawn in a 5 ml
syringe) was chosen arbitrarily. During standard veno-
graphies, we use a 1:1 ratio (2 ml of contrast and 2 ml of
normal saline, predrawn in a 5 ml syringe). In this study by
increasing the ratio of saline to contrast, only 1 ml of contrast
was used per single injection. Similar outcomes may be
obtained by using a 1:2 or other dilution ratios, as long as the
actual contrast dose remains low. The contrast agent used in
this study is a nonionic, low-osmolar monomeric agent. The
overall safety observed in this study might not be repro-
ducible using ionic, high osmolar contrast media.
The 7.8 ml mean contrast volume in this study is low
compared to other endovascular fistula salvage procedures in
the literature. This was achieved by a combination of diluting
the contrast and by targeting the procedure to the one or two
most significant lesions that are preventing maturation of the
fistula. Physical examination played a vital role in the
decision making process. If a fistula was noted to have
multiple significant lesions or a resistant lesion, the patient
would be followed with a repeat examination and possible
reintervention. The C-arm fluoroscope used for this study
performed digital subtraction angiography at a minimum of
15 frames per second (usually 30 frames per second);
therefore, providing adequate imaging when using a 1:3
diluted contrast. A C-arm Fluoroscope performing digital
subtraction angiography at a lower frame per second or
further diluting the contrast with saline may provide
suboptimal imaging.
CONCLUSION
This study demonstrates that in patients with advanced CKD,
fistulas can successfully be salvaged using small contrast
volumes with a low CIN incidence. A significant proportion
of patients in this study were able to initiate dialysis using
their fistula, thus entirely avoiding catheter use. Prospective
trials using low-osmolar or iso-osmolar contrast media
should be performed in patients with stage 4 CKD who
require percutaneous procedures for nonmaturing or throm-
bosed AVF.
MATERIALS AND METHODS
All consecutive procedures performed in patients with stage 4 CKD
and nonmaturing access between 1 January 2002 and 31 December
2004, were identified retrospectively from the central database of the
Arizona Kidney Disease and Hypertension Surgery Center
(AKDHC). There has been a protocol in place for performing and
following the outcome of endovascular procedures in all CKD
patients, details of which are documented in this section. All
interventional procedures were performed by three nephrologists,
certified by the American Society of Diagnostic and Interventional
Nephrology (ASDIN). Of the 36 patients identified, 34 had complete
medical records and were included in this analysis. A total of 65
procedures were performed in the study cohort. The reason for
referral in all cases was an immature or clotted access. No patient
had been on dialysis in the past.
Pretreatment evaluation
Patients were evaluated in the AKDHC preprocedure unit, where the
interventional nephrologist performed a detailed history and
physical examination. Particular attention was given to the
examination of the vascular access in order to tailor the
endovascular procedure. Examination of the fistula began with the
assessment of the feeding artery and arterial anastamosis. Pulse
augmentation was performed by compression of the AVF to assess
the inflow.23 The AVF vein was inspected for presence of any large
accessory veins and outflow stenosis was predicted by hyperpulsa-
tility of the fistula.22 After the evaluation, the nephrologist planned a
targeted endovascular procedure, based specifically on the exam
findings. Each patient received an intravenous bolus of 500–750 ml
of isotonic saline.
Treatment
Patients were transferred to the interventional suite. Intravenous
fentanyl citrate (Cephalon Inc., West Chester, PA, USA) and
midazolam hydrochloride (Faulding Pharmaceutical Company,
Paramus, NJ, USA) were administered by a certified nurse under
the guidance of the nephrologist, to achieve conscious sedation. All
patients were monitored with continuous electrocardiography, pulse
oximetry and standard vital sign determinations. The AVF was
cannulated using an 18- or 21-gauge needle. A seven French sheath
was inserted. The direction of sheath placement was based on the
clinical examination. For example, if an inflow problem was
detected, the sheath was seated in a retrograde manner. A Kumpe
catheter (Angiodynamics, Queensbury, NY, USA) over a roadrunner
wire (Cook Inc., Bloomington, IN, USA) was passed across the
arterial anastamosis and venography performed. If an outflow lesion
was suspected by examination, the sheath was placed in an antegrade
manner and venography performed. In these cases, the inflow was
assessed by manual occlusion of the fistula, causing reflux of
contrast across the arterial anastamosis.
The contrast was diluted in a 1:3 ratio with normal saline (using
1 ml of contrast and 3 ml of normal saline, predrawn in a 5 ml
syringe). The contrast agent used was Ioxilan (Oxilan-300; Cook
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Imaging Corp., Bloomington, IN, USA), a nonionic, low-osmolar
monomer. Stenoses greater than 50% were treated with balloon
angioplasty. The maximum balloon inflation pressures were 1–2
atmospheres above the pressure at which the waist in the balloon
disappeared. Balloons were inflated for 30–60 seconds. For arterial
and arterial anastamotic lesions, an Ultrathin balloon of 4–6 mm
(Boston Scientific, Natick, MA, USA) was used. Lesions in the AV
fistula main vein were treated with 6–8 mm balloons. The lesions
were classified based on their location within the vascular tree: the
feeding artery, the first few centimeters of the vein near the
anastamosis called the Juxta-anastamotic segment, the AVF body,
the proximal draining outflow vein (cephalic arch is an example of a
proximal outflow vein), and finally the central venous system. Large
accessory veins diverting flow away from the fistula were selectively
treated by surgical ligation. The technique of accessory vein ligation
was as follows: The skin over the accessory vein close to the point at
which it entered the fistula was infiltrated with 1% Lidocaine, and
using sharp and blunt dissection the accessory vein was isolated.
A surgical clip was placed across the width of the vein, thus completely
obliterating flow. Successful ligation was then confirmed by
performing a repeat fistulogram. Thrombosed fistulas were treated
with a combination of mechanical and pharmacological thrombec-
tomy, as described by Schon et al.24 Following instillation of 1–2 mg
of Tissue Plasminogen Activator (t-PA) within the thrombus,
manual maceration was used to dissolve the clot. Then balloon
inflation was performed to detect the critical lesions. Lesions of
greater than 50% stenosis were dilated with angioplasty.
Serum creatinine was measured prior to the intervention in all
patients, and patients were instructed to have repeat serum
creatinine levels drawn at post intervention day 2 and day 7 by
the referring nephrologist. All patients were followed for 2 weeks
post intervention to ensure they had completed the blood test and to
document the need for HD. This was accomplished by phone calls to
either the patient or the responsible nephrologist. A significant rise
in the creatinine level after 1 week would initiate further follow-up
by the referring nephrologist. All patients with a rise in creatinine
had repeat measurements within 10–14 days postprocedure.
For the patients noted to have multiple lesions, a staged
(two-step) procedure was planned in order to minimize contrast
exposure. The most significant flow-limiting lesion was treated on
the first visit, followed by repeat examination and angiography 4–6
weeks following the initial intervention.
Data collection
Data collected from the database and patient chart included the date
of access creation, date of procedure, type of procedure performed,
location and number of lesions, amount of contrast used per
procedure, pre, 2- and 7-day creatinine, need for acute dialysis,
complications, date of dialysis initiation, type of access used to
initiate dialysis, and patient status at the end of the study period.
The primary outcome of the study was to determine the safety of
radiocontrast use in this population, as measured by the incidence
of CIN. For the purposes of this study, CIN was defined as a
25% increase in serum creatinine 2 days or 7 days post
intervention25 or the need for HD in the 2-week post intervention
period. The secondary outcome was access patency at the initiation
of dialysis.
Data analysis
Baseline demographic, clinical, and laboratory data are summarized
as means for continuous variables, and as proportions for
categorical variables. To describe the impact of the procedure on
renal function, the number of procedures complicated by CIN (25%
increase in serum creatinine) is reported, along with 95% confidence
intervals for mean change in creatinine from baseline at day 2
(n¼ 50) and day 7 (n¼ 65). Mean creatinine values at baseline and
day 7 were also compared by paired t-test. All other comparisons
were made using unpaired t-tests, with a P-value of o0.05
considered statistically significant. Statistical analysis was performed
using Microsoft Excel 2000 software.
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